Donanemab, Eli Lilly’s New Groundbreaking Alzheimer’s Drug
Dr. Keith Vossel, Neurologist and Director of the UCLA Mary S. Easton Center for Alzheimer’s Research and Care, was interviewed by MarketWatch on May 3, 2023, about his perception of a new groundbreaking Alzheimer’s medication, donanemab, by Eli Lilly, and on the unknown costs associated with the new drug and related tests.
Related Articles
UCLA Develops New Alzheimer's Disease Therapeutic
Dr. Varghese John, Dr. Istvan Mody, and colleagues were highlighted in a UCLA article about their recent therapeutic development, targeting ...
A More Inclusive Framework for Alzheimer’s Disease
The Easton Center, ELHA Lab, UCLA Neurology, Alzheimer's Los Angeles, and community leaders are working together bridging the gap between health disparities ...
Healthy Body. Healthy Mind.
In the Summer Edition of Keiro Connect, Dr. Kevin Bickart discussed physical activity, including dancing, to improve brain health and prevent dementia ...
An In-Depth Interview on Various Neurodegenerative Diseases
Dr. Keith Vossel was interviewed by Dr. Marc Siegel from Doctor Radio/Sirius XM about a wide spectrum of neurodegenerative diseases, including ...